BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gonçalves M, Mignani S, Rodrigues J, Tomás H. A glance over doxorubicin based-nanotherapeutics: From proof-of-concept studies to solutions in the market. Journal of Controlled Release 2020;317:347-74. [DOI: 10.1016/j.jconrel.2019.11.016] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 18.5] [Reference Citation Analysis]
Number Citing Articles
1 Jones IC, Dass CR. Doxorubicin-induced cardiotoxicity: causative factors and possible interventions. J Pharm Pharmacol 2022:rgac063. [PMID: 35994421 DOI: 10.1093/jpp/rgac063] [Reference Citation Analysis]
2 Wang Z, Li J, Lin G, He Z, Wang Y. Metal complex-based liposomes: Applications and prospects in cancer diagnostics and therapeutics. J Control Release 2022;348:1066-88. [PMID: 35718211 DOI: 10.1016/j.jconrel.2022.06.012] [Reference Citation Analysis]
3 Liang J, Guo R, Xuan M, Sun Q, Wu W. An Acid-Sensitive Nanofiber Conjugate Based on a Short Aromatic Peptide for Targeted Delivery of Doxorubicin in Liver Cancer. IJN 2022;Volume 17:2961-73. [DOI: 10.2147/ijn.s359642] [Reference Citation Analysis]
4 Sohail M, Yu B, Sun Z, Liu J, Li Y, Zhao F, Chen D, Yang X, Xu H. Complex polymeric nanomicelles co-delivering doxorubicin and dimethoxycurcumin for cancer chemotherapy. Drug Deliv 2022;29:1523-35. [PMID: 35611890 DOI: 10.1080/10717544.2022.2073403] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Gnoatto JA, Morás AM, Vitor de Oliveira J, Arndt E, Dallegrave A, Borba da Cunha AC, Moura DJ, Zimnoch dos Santos JH. PEGylated and zwitterated silica nanoparticles as doxorubicin carriers applied in a breast cancer cell line: Effects on protein corona formation. Journal of Drug Delivery Science and Technology 2022;71:103325. [DOI: 10.1016/j.jddst.2022.103325] [Reference Citation Analysis]
6 An P, Fan D, Guo Z, Liu FY, Li CF, Yang D, Wang MY, Yang Z, Tang QZ. Bone morphogenetic protein 10 alleviates doxorubicin-induced cardiac injury via signal transducer and activator of transcription 3 signaling pathway. Bioengineered 2022;13:7471-84. [PMID: 35293279 DOI: 10.1080/21655979.2022.2048994] [Reference Citation Analysis]
7 Jeevanandam J, Kiew SF, Boakye-Ansah S, Lau SY, Barhoum A, Danquah MK, Rodrigues J. Green approaches for the synthesis of metal and metal oxide nanoparticles using microbial and plant extracts. Nanoscale 2022;14:2534-71. [PMID: 35133391 DOI: 10.1039/d1nr08144f] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 23.0] [Reference Citation Analysis]
8 Ashrafizadeh M, Saebfar H, Gholami MH, Hushmandi K, Zabolian A, Bikarannejad P, Hashemi M, Daneshi S, Mirzaei S, Sharifi E, Kumar AP, Khan H, Heydari Sheikh Hossein H, Vosough M, Rabiee N, Thakur Kumar V, Makvandi P, Mishra YK, Tay FR, Wang Y, Zarrabi A, Orive G, Mostafavi E. Doxorubicin-loaded graphene oxide nanocomposites in cancer medicine: Stimuli-responsive carriers, co-delivery and suppressing resistance. Expert Opin Drug Deliv 2022. [PMID: 35152815 DOI: 10.1080/17425247.2022.2041598] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
9 Phillips MC, Mousa SA. Clinical application of nano-targeting for enhancing chemotherapeutic efficacy and safety in cancer management. Nanomedicine (Lond) 2022. [PMID: 35118878 DOI: 10.2217/nnm-2021-0361] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
10 Gonçalves M, Kairys V, Rodrigues J, Tomás H. Polyester Dendrimers Based on Bis-MPA for Doxorubicin Delivery. Biomacromolecules 2022;23:20-33. [PMID: 34870412 DOI: 10.1021/acs.biomac.1c00455] [Reference Citation Analysis]
11 Jeevanandam J, Kiew SF, Boakye-ansah S, Lau SY, Barhoum A, Danquah MK, Rodrigues J. Green approaches for the synthesis of metal and metal oxide nanoparticles using microbial and plant extracts. Nanoscale 2022;14:2534-71. [DOI: 10.1039/d1nr08144f] [Reference Citation Analysis]
12 Müllerová M, Maciel D, Nunes N, Wrobel D, Stofik M, Červenková Št Astná L, Krupková A, Cuřínová P, Nováková K, Božík M, Malý M, Malý J, Rodrigues J, Strašák T. Carbosilane Glycodendrimers for Anticancer Drug Delivery: Synthetic Route, Characterization, and Biological Effect of Glycodendrimer-Doxorubicin Complexes. Biomacromolecules 2021. [PMID: 34928129 DOI: 10.1021/acs.biomac.1c01264] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Müllerová M, Maciel D, Nunes N, Wrobel D, Stofik M, Červenková Št́astná L, Krupková A, Cuřínová P, Nováková K, Božík M, Malý M, Malý J, Rodrigues J, Strašák T. Carbosilane Glycodendrimers for Anticancer Drug Delivery: Synthetic Route, Characterization, and Biological Effect of Glycodendrimer–Doxorubicin Complexes. Biomacromolecules 2022;23:276-90. [DOI: 10.1021/acs.biomac.1c01264] [Reference Citation Analysis]
14 Zhang Z, Ji Y, Lin C, Tao L. Thermosensitive hydrogel-functionalized gold nanorod/mesoporous MnO2 nanoparticles for tumor cell-triggered drug delivery. Mater Sci Eng C Mater Biol Appl 2021;131:112504. [PMID: 34857290 DOI: 10.1016/j.msec.2021.112504] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Xiang Y, Chen L, Liu C, Yi X, Li L, Huang Y. Redirecting Chemotherapeutics to the Endoplasmic Reticulum Increases Tumor Immunogenicity and Potentiates Anti-PD-L1 Therapy. Small 2021;:e2104591. [PMID: 34859582 DOI: 10.1002/smll.202104591] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
16 Sohail M, Sun Z, Li Y, Gu X, Xu H. Research progress in strategies to improve the efficacy and safety of doxorubicin for cancer chemotherapy. Expert Rev Anticancer Ther 2021;21:1385-98. [PMID: 34636282 DOI: 10.1080/14737140.2021.1991316] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
17 Zeng Y, Xiang Y, Sheng R, Tomás H, Rodrigues J, Gu Z, Zhang H, Gong Q, Luo K. Polysaccharide-based nanomedicines for cancer immunotherapy: A review. Bioactive Materials 2021;6:3358-82. [DOI: 10.1016/j.bioactmat.2021.03.008] [Reference Citation Analysis]
18 Barbălată CI, Porfire AS, Sesarman A, Rauca VF, Banciu M, Muntean D, Știufiuc R, Moldovan A, Moldovan C, Tomuță I. A Screening Study for the Development of Simvastatin-Doxorubicin Liposomes, a Co-Formulation with Future Perspectives in Colon Cancer Therapy. Pharmaceutics 2021;13:1526. [PMID: 34683821 DOI: 10.3390/pharmaceutics13101526] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
19 Helbert A, von Wronski M, Mestas JL, Tardy I, Bettinger T, Lafon C, Hyvelin JM, Padilla F. Ultrasound Molecular Imaging for the Guidance of Ultrasound-Triggered Release of Liposomal Doxorubicin and Its Treatment Monitoring in an Orthotopic Prostatic Tumor Model in Rat. Ultrasound Med Biol 2021;47:3420-34. [PMID: 34503895 DOI: 10.1016/j.ultrasmedbio.2021.07.022] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Satapathy MK, Yen TL, Jan JS, Tang RD, Wang JY, Taliyan R, Yang CH. Solid Lipid Nanoparticles (SLNs): An Advanced Drug Delivery System Targeting Brain through BBB. Pharmaceutics 2021;13:1183. [PMID: 34452143 DOI: 10.3390/pharmaceutics13081183] [Cited by in Crossref: 3] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
21 Mojarad-Jabali S, Farshbaf M, Walker PR, Hemmati S, Fatahi Y, Zakeri-Milani P, Sarfraz M, Valizadeh H. An update on actively targeted liposomes in advanced drug delivery to glioma. Int J Pharm 2021;602:120645. [PMID: 33915182 DOI: 10.1016/j.ijpharm.2021.120645] [Cited by in Crossref: 2] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
22 Zielińska A, Szalata M, Gorczyński A, Karczewski J, Eder P, Severino P, Cabeda JM, Souto EB, Słomski R. Cancer Nanopharmaceuticals: Physicochemical Characterization and In Vitro/In Vivo Applications. Cancers (Basel) 2021;13:1896. [PMID: 33920840 DOI: 10.3390/cancers13081896] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
23 Olim F, Neves AR, Vieira M, Tomás H, Sheng R. Self‐Assembly of Cholesterol‐Doxorubicin and TPGS into Prodrug‐Based Nanoparticles with Enhanced Cellular Uptake and Lysosome‐Dependent Pathway in Breast Cancer Cells. Eur J Lipid Sci Technol 2021;123:2000337. [DOI: 10.1002/ejlt.202000337] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
24 Bessone F, Dianzani C, Argenziano M, Cangemi L, Spagnolo R, Maione F, Giraudo E, Cavalli R. Albumin nanoformulations as an innovative solution to overcome doxorubicin chemoresistance. Cancer Drug Resist 2021;4:192-207. [PMID: 35582009 DOI: 10.20517/cdr.2020.65] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
25 Zeng Y, Xiang Y, Sheng R, Tomás H, Rodrigues J, Gu Z, Zhang H, Gong Q, Luo K. Polysaccharide-based nanomedicines for cancer immunotherapy: A review. Bioact Mater 2021;6:3358-82. [PMID: 33817416 DOI: 10.1016/j.bioactmat.2021.03.008] [Cited by in Crossref: 29] [Cited by in F6Publishing: 19] [Article Influence: 29.0] [Reference Citation Analysis]
26 Li J, Li X, Xie P, Liu P. Regulation of drug release performance using mixed doxorubicin-doxorubicin dimer nanoparticles as a pH-triggered drug self-delivery system. Journal of Pharmaceutical Analysis 2021. [DOI: 10.1016/j.jpha.2021.03.001] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Xu B, Yuan L, Hu Y, Xu Z, Qin JJ, Cheng XD. Synthesis, Characterization, Cellular Uptake, and In Vitro Anticancer Activity of Fullerenol-Doxorubicin Conjugates. Front Pharmacol 2020;11:598155. [PMID: 33568999 DOI: 10.3389/fphar.2020.598155] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
28 Qi M, Xie L, Duan G. Adriamycin-resistant cells are significantly less fit than adriamycin-sensitive cells in cervical cancer. Open Life Sci 2021;16:53-60. [PMID: 33817298 DOI: 10.1515/biol-2021-0004] [Reference Citation Analysis]
29 Mishra AK, Lim J, Lee J, Park S, Seo Y, Hwang H, Kim JK. Control drug release behavior by highly stable and pH sensitive poly(N-vinylpyrrolidone)-block-poly(4-vinylpyridine) copolymer micelles. Polymer 2021;213:123329. [DOI: 10.1016/j.polymer.2020.123329] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
30 Jaudoin C, Agnely F, Nguyen Y, Ferrary E, Bochot A. Nanocarriers for drug delivery to the inner ear: Physicochemical key parameters, biodistribution, safety and efficacy. Int J Pharm 2021;592:120038. [PMID: 33159985 DOI: 10.1016/j.ijpharm.2020.120038] [Cited by in Crossref: 3] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
31 Pérez-López A, Martín-Sabroso C, Torres-Suárez AI, Aparicio-Blanco J. Timeline of Translational Formulation Technologies for Cancer Therapy: Successes, Failures, and Lessons Learned Therefrom. Pharmaceutics 2020;12:E1028. [PMID: 33126622 DOI: 10.3390/pharmaceutics12111028] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
32 Tan B, Huang L, Wu Y, Liao J. Advances and trends of hydrogel therapy platform in localized tumor treatment: A review. J Biomed Mater Res A 2021;109:404-25. [PMID: 32681742 DOI: 10.1002/jbm.a.37062] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
33 Zhong J, Zhang J, Yu X, Zhang X, Dian L. Olmutinib Reverses Doxorubicin Resistance in ETS1-Overexpressing Leukemia Cells. Med Sci Monit 2020;26:e924922. [PMID: 32830792 DOI: 10.12659/MSM.924922] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
34 Iannazzo D, Celesti C, Espro C. Recent Advances on Graphene Quantum Dots as Multifunctional Nanoplatforms for Cancer Treatment. Biotechnol J 2021;16:e1900422. [PMID: 32618417 DOI: 10.1002/biot.201900422] [Cited by in Crossref: 7] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
35 Caccamo D, Currò M, Ientile R, Verderio EA, Scala A, Mazzaglia A, Pennisi R, Musarra-Pizzo M, Zagami R, Neri G, Rosmini C, Potara M, Focsan M, Astilean S, Piperno A, Sciortino MT. Intracellular Fate and Impact on Gene Expression of Doxorubicin/Cyclodextrin-Graphene Nanomaterials at Sub-Toxic Concentration. Int J Mol Sci 2020;21:E4891. [PMID: 32664456 DOI: 10.3390/ijms21144891] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
36 Laksee S, Sansanaphongpricha K, Puthong S, Sangphech N, Palaga T, Muangsin N. New organic/inorganic nanohybrids of targeted pullulan derivative/gold nanoparticles for effective drug delivery systems. Int J Biol Macromol 2020;162:561-77. [PMID: 32553955 DOI: 10.1016/j.ijbiomac.2020.06.089] [Cited by in Crossref: 7] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
37 Jiang T, Zhang C, Sun W, Cao X, Choi G, Choy J, Shi X, Guo R. Doxorubicin Encapsulated in TPGS‐Modified 2D‐Nanodisks Overcomes Multidrug Resistance. Chem Eur J 2020;26:2470-7. [DOI: 10.1002/chem.201905097] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
38 Argenziano M, Gigliotti CL, Clemente N, Boggio E, Ferrara B, Trotta F, Pizzimenti S, Barrera G, Boldorini R, Bessone F, Dianzani U, Cavalli R, Dianzani C. Improvement in the Anti-Tumor Efficacy of Doxorubicin Nanosponges in In Vitro and in Mice Bearing Breast Tumor Models. Cancers (Basel) 2020;12:E162. [PMID: 31936526 DOI: 10.3390/cancers12010162] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]